|
|
|
| home > white papers > High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts - ILC Dover |
|
|
 WHITE PAPERS |
|
ILC Dover
|
|
High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts
|
|
As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
RWS Life Sciences Welcomes New VP of Quality
RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice
President, Global Quality and Process, in charge of the strategic
direction and implementation of its Quality system, underlying
organizational processes, and change management.
More info >> |
|
 |
White Papers |
 |
|
Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands
West Pharmaceutical Services, Inc.
The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >> |
|
 |
Industry Events |
 |
SMI Immuno-Oncology Conference
25-27 September 2018, Copthorne Tara Hotel, London, UK
Immuno-Oncology is a fast-paced field with massive potential to deliver
successful and durable cancer therapies, and SMi's Immuno-Oncology Conference will focus on a few key areas of
the field with a representation of the whole industry under each area. These
areas will be drawn together to look towards the future of Immuno-oncology and
how the field can progress.
More info >> |
|
|
|
